Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 5/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ICMT | O60725 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26990598 | 1.00 | LMNA (0.34) | LMNANPSR1KDM4EATMTDP1 | |
| SCHEMBL30726987 | 0.75 | LMNA (0.37) | LMNANPSR1KDM4EATMTDP1 | |
| SCHEMBL26983676 | 0.75 | LMNA (0.37) | LMNANPSR1KDM4EATMTDP1 | |
| SCHEMBL27165059 | 0.75 | LMNA (0.37) | LMNANPSR1KDM4EATMTDP1 | |
| SCHEMBL30727059 | 0.75 | LMNA (0.37) | LMNANPSR1KDM4EATMTDP1 | |
| SCHEMBL26990378 | 0.66 | LMNA (0.36) | LMNANPSR1KDM4EATMTDP1 | |
| SCHEMBL5517424 | 0.66 | KDM4E (0.45) | LMNANPSR1KDM4EATMTDP1 | |
| SCHEMBL26990607 | 0.66 | — | — | |
| SCHEMBL30727002 | 0.66 | C5AR1 (0.35) | LMNANPSR1KDM4EATMTDP1 | |
| SCHEMBL3413377 | 0.66 | SLC6A4 (0.47) | LMNANPSR1ALDH1A1C5AR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739680-A1 | SOLID FORMS OF TRPV4 ANTAGONISTS | Actio Biosciences, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250333403-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12391683-B2 | Therapeutic compounds and methods | ACTIO BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4551572-A1 | THERAPEUTIC COMPOUNDS AND METHODS | Actio Biosciences, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119790051-A | Therapeutic compounds and methods | 爱克堤欧生物科学股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025014818-A1 | SOLID FORMS OF GSK2798745, A TRPV4 ANTAGONIST | ACTIO BIOSCIENCES, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240287055-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11987577-B2 | Therapeutic compounds and methods | ACTIO BIOSCIENCES, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240076294-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2024011214-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333403-A1 | THERAPEUTIC COMPOUNDS AND METHODS | TRPV4, TRPV3, TRPV2 | LMNA 2459/4885NPSR1 143/4885KDM4E 2678/4885 |
| US-20240287055-A1 | THERAPEUTIC COMPOUNDS AND METHODS | TRPV4, TRPV3, TRPV2 | LMNA 2459/4885NPSR1 143/4885KDM4E 2678/4885 |
| US-11987577-B2 | Therapeutic compounds and methods | TRPV4, TRPV3, TRPV2 | LMNA 2459/4885NPSR1 143/4885KDM4E 2678/4885 |
| US-12391683-B2 | Therapeutic compounds and methods | TRPV4, TRPV3, TRPV2 | LMNA 2459/4885NPSR1 143/4885KDM4E 2678/4885 |
| US-20240076294-A1 | THERAPEUTIC COMPOUNDS AND METHODS | TRPV4, TRPV3, TRPV2 | LMNA 2459/4885NPSR1 143/4885KDM4E 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.